11c-er176
Recombinant proteinexperimentalImaging agent
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Sep 10, 2018 (NCT03744312)
Timeline
Indications
Mechanism of action
- Translocator proteinRadiopharmaceutical
TSPO radiopharmaceutical
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 11-carbon
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06384378 | Phase 2 | Mar 17, 2023 | The University of Texas, Dallas |
| NCT04840979 | Phase 2 | May 11, 2021 | Columbia University, National Institute on Aging (NIA) |
| NCT04762719 | Phase 2/Phase 3 (Phase 3) | May 10, 2021 | Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT04576793 | Phase 2 | Nov 1, 2020 | Columbia University, National Institute on Aging (NIA) |
| NCT03958630 | Phase 1 | Jul 5, 2019 | National Institute of Mental Health (NIMH) |
| NCT03744312 | Phase 1/Phase 2 (Phase 2) | Sep 10, 2018 | Columbia University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Columbia University | Academic/Hospital | 3 | 3 | 1 | 2018 |
| National Institute on Aging (NIA) | Government | 2 | 0 | 1 | 2020 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2021 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2021 |
| National Institute of Mental Health (NIMH) | Government | 1 | 1 | 1 | 2019 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2023 |
6 organizations
Page 1 / 1